DOI: 10.5281/zenodo.4052468
title: Reduced metabotropic glutamate receptor subtype 5 in mice and men with fragile X syndrome

description: <em>Measurement of metabotropic glutamate receptor subtype 5 (mGluR<sub>5</sub></em><em>) density in heterozygous </em><em>fmr1 knockout (KO) mouse models </em> A major neuroimaging problem in the examination of mGluR<sub>5</sub>s in the <em>fmr1</em> KO mouse model of fragile X syndrome (FXS) (Dahlhaus R., 2018) is the small volume of the striata and other structures in these mice. Visualizing mGluR<sub>5</sub>s in the tiny structures in the brains of the <em>fmr1</em> KO models is further hindered by the recessive effects of inbreeding or loss of Fragile X Mental Retardation Protein (FMRP). To counteract reduced expression of mGluR<sub>5</sub>s in these models, heterozygous offspring from a KO parent and a wild type parent exhibit the robust expression of mGluR<sub>5</sub>s required for functional imaging studies with relatively poor resolution. Therefore, in order to reduce or eliminate the recessive effects from inbred genetic loci (Yan QJ et al.<em>,</em> 2005) and foster expression of mGluR<sub>5</sub>s, we employed heterozygous male offspring of an <em>fmr1</em> KO FVB strain female and a male of wild-type (C57) (Denman RB 2012a,b; Zupan B et al. 2012) because <em>fmr1</em> KOs and heterozygotes exhibit greater mGluR<sub>5</sub> protein levels (Chen et al. 2012)]. While several techniques exist to estimate the concentration of glutamate in the living brain, including magnetic resonance imaging (MRI) and brain biopsy, positron emission tomography (PET) uniquely provides the optimal means to measure mGluR<sub>5</sub>s. For these reasons, radiotracers that bind to mGluR<sub>5</sub> in the living brain and can be visualized with PET are promising tools to quantify the density and the distribution of mGluR<sub>5</sub>s in <em>Fmr1</em> KO mouse (Hamill TG et al., 2005) and in humans with FXS. [<sup>11</sup>C]ABP688 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-[<sup>11</sup>C]methyl-oxime ([<sup>11</sup>C]ABP688), a noncompetitive and highly selective antagonist for mGluR<sub>5</sub>s (Ametamey SM et al. 2006) has been demonstrated to confirm target engagement of mGluR<sub>5</sub>s in mice ((Ametamey SM et al. 2006; Kim J et al. 2015), baboons (Mathews WB et al. 2014), and humans (DeLorenzo C et al. 2017). <strong>Materials and Methods</strong> <em>Participants</em> <em>fmr1</em> KO mouse model To maximize the expression of mGluR<sub>5</sub>s in the <em>fmr1</em> KO mouse model and to minimize the recessive effects of a full knockout mouse model, we compared and contrasted the density and distribution of mGluR<sub>5</sub>s in six wild-type C57 male mice and six heterozygous FVBxC57 male mice. The heterozygotes were obtained by crossing female <em>fmr1</em> KO mice (bred in FVB as the background strain) with male wild-type C57 mice (FVBxC57) (Yan QJ et al. 2005; Denman RB 2012a,b; Zupan et al. 2012; Kazdoba TM et al. 2014; Berman RF et al. 2014). To test the ability of [<sup>11</sup>C]ABP688 PET to accurately estimate mGluR<sub>5 </sub>density, we compared C57 wild-type and FVBxC57 mice heterozygous for the <em>Fmr1</em> knockout. MicroPET After the induction of anesthesia with isoflurane (0.5-1%; approximately 1 L/min), 6 FVBxC57 male mice and 6 wild type C57 male mice underwent PET on a SuperArgus micro PET/CT (Sedecal, 2020) for 60 min after the intravenous bolus injection of 7.4 to 11.1 MBqs (200 to 300 microcuries) [<sup>11</sup>C]ABP688 via the lateral tail vein. Mice were scanned in pairs of one FVBxC57 and a matched littermate wild type C57 control, placed side by side in the scanner bed aligned so that their heads were upright and centered in the field of view. All scans occurred between 1 PM and 3 PM to avoid the possible effects of diurnal variations on mGluR<sub>5</sub> (DeLorenzo et al. 2017; Castañeda TR et al. 2004; Fuller PM et al. 2006; Meng T et al. 2015). Following each PET scan, a 5-min CT scan was performed for anatomical reference. PET images were analyzed using standard volumes of interest (VOIs) derived from the mouse brain atlas of the Laboratory for Neuro Imaging (Mark and Mary Stevens Neuroimaging and Informatics Institute. 2020; Van Essen DC 2002). Both PET and CT images were specially aligned and normalized to PET space with a perpendicular mid-plane using skull-to-skull and CT-to-standard CT spatial normalization parameters with the SPM5 module (Ashburner J et al., 2004a,b; Nandi et al. 2017). The prepared VOIs were applied to PET frames to obtain tissue time activity curves (TACs) to estimate the nondisplaceable binding potential (BP<sub>ND</sub>) (Innis etal 2007) using the simplified reference tissue method (SRTM) (Lammertsma AA et al. 1996). <em>mGluR<sub>5</sub>s in an fmr1 KO mouse model </em> In contrast to wild type C57 male mice, FVBxC57 heterozygous male mice exhibited significantly greater uptake of [<sup>11</sup>C]ABP688 in the striatum (Two-sample t test, P &lt; 0.05) (Figure 1), but not the cortex, the hippocampus, or the cerebellum. The procedure provides measurements of mGluR<sub>5</sub> in mouse models of FXS. <em>mGluR<sub>5</sub>s in a fmr1 KO mouse model </em> We showed that PET provides a quantitive measurement of mGluR<sub>5</sub>s density in an<em> fmr1</em> KO model of FXS. Unlike the <em>fmr1</em> KO mouse model, our heterozygous <em>fmr1 </em>mouse model exhibited increased mGluR<sub>5</sub> density in the striatum, but not in the cerebellum, the cortex, or the hippocampus (Two-sample t test). Different radiotracers were used for the animal and human studies after the completion of the animal studies with [<sup>11</sup>C]ABP688, as we showed that 3-[<sup>18</sup>F]fluoro-5-(2-pyridinylethynyl)benzonitrile [<sup>18</sup>F]FPEB) (Wong DF et al. 2013)exhibits better reproducibility and higher regional BP<sub>ND</sub> values than [<sup>11</sup>C]ABP688 (Kuwabara H et al. 2011). Since the human studies were performed after the animal studies with [<sup>11</sup>C]ABP688, the radiotracer with optimal properties, [<sup>18</sup>F]FPEB, was employed. Using the same radiotracer for both investigations of animals and humans would improve the ability to compare and contrast findings. Participants with fragile X syndrome (FXS), fragile X syndrome allele size mosaiscism (FXS-M), premutation of the fragile X gene (PM), autism spectrum disorder (ASD), and typical development (TD) underwent positron emission tomography to measure the density and the distribution of metabotropic glutamate receptors subtype 5 (mGluR<sub>5</sub>) in the brain. Participants from the Institute for Neurodegenerative Disorders (IND), New Haven, Connecticut, USA, included 7 men with FXS aged 22.3 to 33.6 (27.1+4.7) years, a man with FXS-M aged 56.6 years, and a women with PM and TD aged 56.3 years. For the men with FXS the height ranged from 67 to 74 (70.33+3.27) inches, the weight ranged from 154 to 285 (203.5+49.61) pounds, and the BMI ranged from 22.0 to 36.6 (28.8+5.7). The man with FXS-M was 70 inches in height, 238 pounds in weight, and had a BMI of 34.1. The woman with PM TD was 65.6 inches in height, 258 pounds, and 42.3 BMI. The man with FXS-M was allele size mosaic (PM 181 CGGs, 20% methylated, and the full-mutation allele 100% methylated). The men with FXS read below the first grade level and the man with FXS-M read at the eighth grade level. All participants from IND were non-Hispanic Caucasians. Participants from Johns Hopkins University (JHU), Baltimore, Maryland, USA included 4 men with FXS,aged 19 to 41 (27.6+9.43) years, 6 men with ASD aged 18 to 22 (20+2.1) years, and 3 individuals (1 man and 2 women) with TD aged 19 to 24 (20.67+2.89) years. . Table S1 lists the concomitant medications of participants from the Institute for Neurodegenerative Disorders (IND), New Haven, Connecticut, USA.. The genetic and neurobehavioral assessments are presented for participants from the Institute for Neurodegenerative Disorders (IND), New Haven, Connecticut, USA, in Table S2 and for participants from the Johns Hopkins University (JHU), Baltimore, Maryland, USA in Table S3. Clinically participants JHUFXS1 and JHUFXS2 did not exhibit ASD. Participant JHUFXS1 withdrew from the study for a family emergency before neurobehavioral testing including symptoms of ASD (Lord et al., 2012) was accomplished. Because of his age participant JHUFSX2 was adminiered module 4 of the ADOS (Lord et al., 2012). Due to his limited speech a lower module would likely appropriately indicate the absence of autism. In other words, the symptoms demonstrated by module 4 of the ADOS (Lord et al. 2012) likely reflect an artifact of the incorrect administration of a module for higher functioning individuals. At JHU recruiting participants was challenging because research with positron emission tomography (PET) had not previously been conducted on people with FXS. Therefore, all participants with FXS at JHU were recruited regardless of the presence of ASD. . The positron emission tomography data and analysis are presented for participants from the Institute for Neurodegenerative Disorders in Table S4 and for participants from the Johns Hopkins University in Table S5. The authors thank Flora Tassone, Ph.D., Department of Biochemistry and Molecular Medicine, School of Medicine, UC Davis Health, Sacramento, California, for providing genetic and protein data about participants. <strong>Disclosures: </strong>We disclose the unlabeled/unapproved use of 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-[<sup>11</sup>C]methyl-oxime ([<sup>11</sup>C]ABP688)
description: This research was made possible by a Radiology BRidge/Development Funding Initiative to STimulate and Advance Research (RAD BriteStar Bridge) Award from the Johns Hopkins University School of Medicine, Baltimore, Maryland, to JRB; the Intellectual & Developmental Disabilities Research Center (U54 HD079123), Kennedy Krieger Institute, Johns Hopkins Medical Institutions. Baltimore, Maryland, to JRB; and the Johns Hopkins Institute for Clinical and Translational Research (ICTR), Johns Hopkins University School of Medicine, Baltimore, Maryland, to JRB, which is funded in part by Grant Number UL1 TR003098 from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS or NIH.
description: {"references": ["Deb S et al. (2007) Dementia Screening Questionnaire for Individuals with Intellectual Disabilities. Br J Psychiatry 190: 440-444. DOI: 10.1192/bjp.bp.106.024984. PMID: 17470960", "Fostein MF et al. (1975) \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12: 189-198. DOI: 10.1016/0022-3956(75)09926-6. PMID: 1202204", "Lord C et al. (2012) Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2). Western Psychological Services (WPS), Torrance, California, USA", "Cambridge Cognition Ltd. Cambridge Neuropsychological Test Automated Battery (CANTAB). Cambridge Cognition Ltd., Cambridge, UK, 2020. Available online: www.cambridgecognition.com (accessed 26 September 2020)", "Benedict RHB et al. (1998) The Hopkins Verbal Learning Test-Revised: normative data and analysis of inter-form and test-retest reliability. Clin. Neuropsychol. 12: 43-55.", "Brandt J et al. (1998) Hopkins Verbal Learning Test-Revised (TM) [HVLT-R(TM)]. Par, Inc., Lutz, Florida, USA", "Shapiro AM et al. (1999) Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin. Neuropsychol. 13: 348-358. DOI: 10.1076/clin.13.3.348.1749. PMID: 10726605", "Road GH. Stanford-Binet Intelligence Scales, 5th Edition (SB-5). Western Psychological Services (WPS), Torrance, California, USA", "Sparrow SS et al. (2020) Vineland Adaptive Behavior Scales, 3rd Edition (Vineland-3). Pearson, San Antonio, Texas, USA", "Dahlhaus R. (2018) Of men and mice: modeling the fragile X syndrome. Front Mol Neurosci 11, 41. DOI: 10.3389/fnmol.2018.00041. PMID: 29599705", "Yan QJ et al. (2005) Suppression two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neurophramacology 49, 1053-1066. doi: 10.1016/j.neuropharm.2005.06.004. Epub 2005 Jul 27. PMID: 16054174.", "Denman RB. (2012v) Introduction: reminiscing on models and modeling. In: Modeling Fragile X Syndrome; Denman, R.B., Ed.; Springer Verlag: Berlin, Germany, 2012; pp. 1-12. doi: 10.1007/978-3-642-21649-7_1", "Denman, RB (2012b) Vignettes: models in absentia. In: Modeling Fragile X Syndrome; Denman, R.B., Ed.; Springer Verlag: Berlin, Germany, 2012; pp. 361-383. DOI 10.1007/978-3-642-21649-7_19", "Zupan B et al. (2012) Fmr-1 as an offspring genetic and a maternal environmental factor in neurodevelopmental disease. In Modeling Fragile X Syndrome; Denman, R.B., Ed.; Springer Verlag: Berlin, Germany, 2012; pp. 243-253.", "Chen, C.-C.; Lu, H.-C.; Bromberg, J.C. (2012) mGluR5 knockout mice display increased dendritic spine densities. Neurosci. Lett. 2012, 524, 65-68. doi: 10.1016/j.neulet.2012.07.014", "Hamill, T.G.; Krause, S.; Ryan, C.; Bonnefous, C.; Govek, S.; Seiders, T.J.; Cosford, N.D.P.; Roppe, J.; Kamenecka, T.; Patel, S.; Gibson, R.E.; Sanabria, S.; Riffel, K.; Eng, W.; King, C.; Yang, X.; Green, M.D.; O'Malley, S.S.; Hargreaves, R.; Burns, H.D. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 2005, 56, 205\u2013216. doi: 10.1002/syn.20147. PMID: 15803497", "Ametamey, S.M.; Kessler, L.J.; Honer, M.; Wyss, M.T.; Buck, A.; Hintermann, S.; Auberson, Y.P.; Gasparini, F.; Schubiger, P.A. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J. Nucl. Med. 2006, 47, 698\u2013705. PMID: 16595505", "Kim, J.; Horti, A.G.; Mathews, W.B.; Pogorelov, V.; Valentine, H.; Brasic, J,R.; Holt, D.P.; Ravert, H.T.; Dannals, R.F.; Zhou, L.; Jedynak, B.; Kamiya, A.; Pletnikov, M.K.; Wong, D.F. Quantitative multi-modal brain autoradiography of glutamatergic, dopaminergic, cannabinoid, and nicotinic receptors in mutant disrupted-in-schizophrenia-1 (DISC1) mice. Mol. Imaging Biol. 2015, 17, 355-363. doi: 10.1007/s11307-014-0786-4. PMID: 25296765", "Mathews, W.B.; Kuwabara, H.; Stansfield, K.; Valentine, H.; Alexander, M.; Kumar, A.; Hilton, J.; Dannals, R.F.; Wong, D.F.; Gasparini, F. Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [11C]ABP688 PET imaging. Synapse 2014, 68, 565\u2013573. doi: 10.1002/syn.21775. Epub 2014 Aug 19. PMID: 25098663", "DeLorenzo, C.; Gallezot, J.-D.; Gardus, J.; Yang, J.; Planeta, B.; Nabulsi, N.; Ogden, R.T.; Labaree, D.C.; Huang, Y.H.; Mann, J.J.; Gasparini, F.; Lin, X.; Javitch, J.A.; Parsey, R.V.; Carson, R.E.; Esterlis, I. In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB. J. Cereb. Blood Flow Metab. 2017, 37, 2716\u20132727. DOI: 10.1177/0271678X16673646doi: 10.1177/0271678X16673646. Epub 2016 Jan 1. PMID: 27742888 PMCID: PMC5536783", "Kazdoba, T.M.; Leach, P.T.; Silverman, J.L.; Crawley, J.N. Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable Rare Dis Res 2014, 3(4), 118-133. doi: 10.5582/irdr.2014.01024. PMCID: PMC4298642. PMID: 25606362.", "Berman, R.F.; Buijsen, R.A.M.; Usdin, K.; Pintado, E.; Kooy, F.; Pretto, D.; Pessah, I.N.; Nelson, D.L.; Zalewski, Z.; Charlet-Bergeurand, N.; Willemsen, R.; Hukema, R.K. Mouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndrome. J. Neurodev. Disord. 2014, 6, 25. Available online: http://www.jneurodevdisorders.com/content/6/1/25 (accessed on 1 August 20200) doi: 10.1186/1866-1955-6-25. Epub 2014 Jul 30. PMID: 25136376", "Sedecal. SuperArgus PET/CT. Sedecal: Madrid, Spain, 2020. Available online: https://www.sedecal.com/en/products/superargus-pet-ct/ (accessed on 1 August 2020).", "Casta\u00f1eda, T.R.; de Prado, B.M.; Prieto, D.; Mora, F. Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. J. Pineal Res. 2004, 36, 177-185. doi: 10.1046/j.1600-079x.2003.00114.x. PMID: 15009508", "Fuller, P.M.; Gooley, J.J.; Saper, C.B. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. J. Biol. Rhythms 2006, 21, 482-493. doi: 10.1177/0748730406294627. PMID: 17107938", "Meng, T.; Yuan, S.; Zheng, Z.; Liu, T.; Lin, L. Effects of endogenous melatonin on glutatmate and GABA rhythms in the striatum of unilateral 6-hydroxydopamine-lesioned rats. Neuroscience 2015, 286, 308-315. doi: 10.1016/j.neuroscience.2014.11.062. Epub 2014 Dec 8. PMID: 25499317", "Mark and Mary Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, California, USA. Laboratory of Neuro Imaging. Available online: link.usc.edu (accessed on 20 August 2020)", "Van Essen, D.C. Surface-based atlases of cerebellum cortex in human, macaque, and mouse. Ann. N. Y. Acad. Sci. 2002, 978, 468-479", "Ashburner, J.; Friston, K.J. Rigid body registration. In: Human Brain Function, 2nd ed.; Frackowiak, R.S.J., Ashburner, J., Penny, W.D., Zeki, S., Friston, K.J., Frith, C., Dolan, R., Price, C.J., Eds.; Academic: Waltham, Massachusetts, USA, 2004a, pp., 635-654", "Ashburner, J.; Friston, K.J. Rigid body registration. In: Human Brain Function, 2nd ed.; Frackowiak, R.S.J., Ashburner, J., Penny, W.D., Zeki, S., Friston, K.J., Frith, C., Dolan, R., Price, C.J., Eds.; Academic: Waltham, Massachusetts, USA, 2004b, pp., 635-654", "Nandi, A.; Kuwabara, H.; Nakano, M.; Fedorko, J.; Zhao, Q.; Roberts, J.; Valentine, H.; Wong, D. A managed analysis environment for quantification of neuroimaging studies with microPET. J. Nucl. Med. 2017, 58 (supplement 1), 296. Available online: http://jnm.snmjournals.org/content/58/supplement_1/296.short. (accessed on 14 April 2020). [abstract]", "Innis, R.B.; Cunninghamm V.J.; Delforge, J.; Fujita, M.; Gjedde, A.; Gunn, R.N.; Holden, J.; Houle, S.; Huang, S.C.; Ichise, M.; Iida, H.; Ito, H.; Kimura, Y.; Koeppe, R.A.; Knudsen, G.M.; Knuuti, J.; Lammertsma, A.A.; Laruelle, M.; Logan, J.; Maguire, R.P.; Mintun, M.A.; Morris, E.D.; Parsey, R.; Price, J.C.; Slifstein, M.; Sossi, V.; Suhara, T.; Votaw, J.R.; Wong, D.F.; Carson, R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27, 1533-1539. doi: 10.1038/sj.jcbfm.9600493. Epub 2007 May 9. PMID: 17519979.", "Lammertsma, A.A.; Hume, S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 1996, 4, 153\u2013158. doi: 10.1006/nimg.1996.0066. PMID: 9345505", "Kuwabara, H.; Chamroonrat, W.; Mathews, W.; Waterhouse, R.; Brasic, J.; Guevara, M.R.; Kumar, A.; Hamill, T.; Mozley, P.D.; Wong, D.F. Evaluation of 11C- ABP688 and 18F -FPEB for imaging mGluR5 receptors in the human brain. J. Nucl. Med. 2011, 52 (supplement 1), 390. [abstract]", "Wong, D.F.; Waterhouse, R.; Kuwabara, H.; Kim, J.; Bra\u0161i\u0107, J.R.; Chamroonrat, W.; Stabins, M.; Holt, D.P.; Dannals, R.F.; Hamill, T.G.; Mozley, P.D. 18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. J. Nucl. Med. 2013, 54, 388-396. doi: 10.2967/jnumed.112.107995. Epub 2013 Feb 12. PMID: 23404089"]}